CNBC Stock Blog
- Portfolio Prep for Next Week: 'Don't Get Crazy'
- Strategists on Dubai: Avoid 'Rash Moves' Now
- Dubai Stock Market Fear Has 'Legs': Dennis Gartman
- Surprising Options Trades in TiVo Shares
- 10 Dividend Picks For Your Portfolio: Chief Investors
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Retail Earnings and Sales to Improve in Q4: Analyst
- 4 Food Stocks to Stuff in Your Portfolio: Analyst
- S&P at 1050-1200 Trading Range Next Year: Strategist
- U.S. Stocks Fall on Dubai Worries
- Black Friday at Best Buy
- Strategists on Dubai: Avoid 'Rash Moves' Now
- Longer Lines, Fuller Carts This Black Friday
- Dubai Stock Market Fear Has 'Legs': Dennis Gartman
- Obama's Emission Reduction Pledge Paints Future for Autos
- Is Super Bowl Halftime Act Too Old?
- Surprising Options Trades in TiVo Shares
- EA Sports Hopes to Pump Up Sales Through Pop-Up Locations
- Dubai's Debt Woes Signal New Era for Creditors
- Next Week: Cash In Now Or Wait For A Santa Rally?
- Fed Audit Would Hurt Economic Prospects: Bernanke
- Dubai Stock Selloff May Bring Buying Opportunity
- Longer Lines, Fuller Carts This Black Friday
- Big US Banks May Be Forced to Raise Capital: Bove
- Bank of America Amends Pay for Senior Executives
- Dubai Fallout Is a Correction, Not Another Crisis: El-Erian
- Tiger Woods Out of Hospital After Accident
RSS FEED
Text Size 
CNBC News Associate
Markets opened higher on Wednesday, helped by a positive jobs data. Where should investors be looking right now? Bernard Lirola, fund manager of the Needham Aggressive Growth Fund, shared his favorite stock picks.
Lirola's Recommendations:
Trimble Navigation [TRMB
Loading...
()
]—“They create efficiencies for businesses,” Lirola told CNBC.
“They do it through a combination of equipment and software…It is an efficiency driven company…I’m hoping the stock will gain 50 percent in 2 years.”
Express Scripts [ESRX
Loading...
()
]—“They try to drive the cost of drugs down for corporations and also for government,” he said of the firm.
“We see them doubling their earnings to about $7 a share in 3 years, so we’re very happy to pay just 15 times next year earnings for that growth.”
Gilead Sciences [GILD
Loading...
()
]—“They are the leading viral drug solution company in the world—75 percent of HIV patients in the U.S. are treated with their drugs and only 65 percent in Europe, so there’s growth opportunity there,” he said.
“But [Gilead] is also expanding their research to other lines of viral issues, so I see them being taken over by pharmaceutical companies because anti-viral research is very important. They trade at $43, I hope that they’d be taken out in 2 to 3 years at $75 a share.”
______________________________
Other Market Opinions:
- Stock Picker: Buffett Will Target These Industries Next
- 4 High Dividend Yielding Stocks: Portfolio Manager
- Where to Invest Now: Two Strategists' Views
______________________________
CNBC Data Pages:
______________________________
CNBC Slideshows:
______________________________
______________________________
Disclosures:
No immediate information was available for Lirola or his firm.
______________________________
Data is a real-time snapshot *Data is delayed at least 15 minutes